about
Possible biological and translational significance of mast cells density in colorectal cancerEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerA novel 3D fibril force assay implicates src in tumor cell force generation in collagen networksNovel non-AR therapeutic targets in castrate resistant prostate cancerDasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activityExpression and function of MutT homolog 1 in distinct subtypes of breast cancer.The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.Src inhibitors in the treatment of metastatic bone disease: rationale and clinical dataHigh-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Src Dependent Pancreatic Acinar Injury Can Be Initiated Independent of an Increase in Cytosolic Calcium.iPhos: a toolkit to streamline the alkaline phosphatase-assisted comprehensive LC-MS phosphoproteome investigation.Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets.Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief reportElucidating the identity of resistance mechanisms to prednisolone exposure in acute lymphoblastic leukemia cells through transcriptomic analysis: A computational approach.Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.Molecular profiling of childhood cancer: Biomarkers and novel therapiesActivation of abl family kinases in solid tumors.Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.Reversing multidrug resistance by tyrosine kinase inhibitorsThe potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.A critical role for Lyn kinase in strengthening endothelial integrity and barrier function.CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.Integration of phosphoproteomic, chemical, and biological strategies for the functional analysis of targeted protein phosphorylation.Therapeutic targeting of EPH receptors and their ligands.Pharmacology of Src family kinases and therapeutic implications of their modulators.Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion.Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes.Managing sarcoma: where have we come from and where are we going?Dasatinib-induced Seborrheic Dermatitis-like Eruption.Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation.
P2860
Q27009040-28682234-C7FC-424C-9096-CE91A004A15AQ27010542-1B97EEB7-A6FD-47E3-A33B-70E27CC3DC12Q27335593-09B1019A-E14C-4B61-8AD5-FC66B0EDFB41Q28383663-6072AD4C-90CC-43B2-B53E-EC331ECD27F4Q28468632-F8A34FEB-56BE-4F25-BE23-4289AA2DDB19Q33598769-742402AF-166C-4077-9238-309F229BEBF5Q33881060-279A41C7-81E7-43AF-ADBC-7A2BA6D830BDQ34051933-3A6062BD-3B12-49B7-AA86-3F926DD241A1Q34182834-60FC6515-F9BA-442B-8C89-0C1D9AA39880Q34283282-DA285289-FD18-43FC-B597-86203B8DA47AQ34793419-2B29FC0F-7354-4C79-81A9-0AF3C0C9615BQ34913349-8CE206E5-C9BC-4B4F-965D-20FFFA4DEAB0Q35068051-2D87C3C1-62E5-4960-9710-2D6BD7600E62Q35677049-6E4AFC24-6CB2-46B2-BC0C-795A29CC87A8Q35840886-9D13C491-029E-406C-BE21-041A0BD410DAQ35856573-1821214C-16B4-4B58-A6E1-D5715BC901EAQ35919774-A621753A-5A41-48B5-844B-DC069517EF08Q36250783-957F6842-1E89-42CF-BB81-8686126E202BQ36443421-551BBB73-7043-44DA-B2B5-01A7F59E27D2Q36533121-C03445DF-FFED-4563-96E7-73D06767B564Q37183670-EF9B94A4-8EC9-40FA-A83D-F92F5CA5AA5CQ37304764-133DEEDE-E39F-4B91-8F0D-902DBD0EE20AQ37362851-EBC2B1D6-AE97-4C4E-8990-F01CFE7B2E2BQ37390244-50DB4ED3-D822-46CF-B2BF-FBA76A964310Q37687393-DBFE42C1-28CC-4FCF-80B9-ED9A2783B8C4Q37976467-8883801B-9105-4413-A8DA-285159B8B09BQ38005052-3FC8028F-F8E6-4D33-9FC9-4CEC3BA0D465Q38057720-66D3967B-C515-4204-8E98-B102F21FAE9EQ38174793-DBCB90EF-7FCF-4F38-A5DC-67089D753C40Q38302202-D4BF8681-8E0F-4E88-B714-FF8D841E35B0Q38818048-8B93AF79-A4B0-4B9D-9CD4-C2DC3A198A4BQ38979793-9819DE2B-09B5-49E0-B645-86DB203C46F2Q39110080-9EE465F1-18BA-4FF9-B9EC-56818683261AQ41988197-8F6285AC-E19A-44CE-97C7-28733E4560D2Q43202567-04795933-A054-4143-B580-07FD6467835AQ44296766-640AB456-F3C6-4489-95D4-0BA908DE931CQ45764606-2B4F445B-EE5C-4428-B703-10998B010D12Q48275281-DD8FB45D-84A5-457C-8F70-123287EDCA37Q53156735-BF681219-940D-4748-8F4C-09D26F571E75Q54977781-AB7B0EA6-729A-4942-B5DC-B452BD1A40D3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dasatinib: an anti-tumour agent via Src inhibition.
@ast
Dasatinib: an anti-tumour agent via Src inhibition.
@en
type
label
Dasatinib: an anti-tumour agent via Src inhibition.
@ast
Dasatinib: an anti-tumour agent via Src inhibition.
@en
prefLabel
Dasatinib: an anti-tumour agent via Src inhibition.
@ast
Dasatinib: an anti-tumour agent via Src inhibition.
@en
P2093
P1433
P1476
Dasatinib: an anti-tumour agent via Src inhibition.
@en
P2093
Angelo Vacca
Antonio Gnoni
Ilaria Marech
Nicola Silvestris
Vito Lorusso
P304
P356
10.2174/138945011794751591
P577
2011-04-01T00:00:00Z